Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Concetta Fargnoli

Showing results (181-190 of 284) with videos related to

Pageof 29
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 9, 2026
Age-specific melanoma risk associated with nevi: a pooled analysis from the M-SKIP projectGiulia Doi, Aurora Gaeta, Simone Ribero, et al.
Life (Basel, Switzerland)|January 8, 2025
Correction: Tognetti et al. Pattern Analysis of Benign and Malignant Atypical Melanocytic Skin Lesions of Palms and Soles: Variations of Dermoscopic Features According to Anatomic Site and Personal Experience. <i>Life</i> 2024, <i>14</i>, 659Linda Tognetti, Alessandra Cartocci, Elvira Moscarella, et al.
Cancers|June 13, 2025
Clinical and Histological Predictors of Advanced Basal Cell Carcinoma Recurrence After Complete Response to Hedgehog Pathway Inhibitors: A Retrospective Multicenter Observational StudyMaria Mannino, Massimiliano Scalvenzi, Alessandro Di Stefani, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 12, 2018
MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the melanostrum consortiumAlexander J Stratigos, Maria Concetta Fargnoli, Arcangela De Nicolo, et al.
The Journal of Dermatological Treatment|November 3, 2025
Baricitinib for adult atopic dermatitis: real-world effectiveness, safety, and response predictorsNiccolò Gori, Lucia Di Nardo, Elena Ippoliti, et al.
Acta Dermato-Venereologica|December 3, 2020
Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME StudyMarina Talamonti, Giovanna Malara, Ylenia Natalini, et al.
Biomedicines|October 27, 2022
Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective StudyMartina Burlando, Gabriella Fabbrocini, Claudio Marasca, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 20, 2025
A clinical-dermoscopic risk scoring model for early melanoma of the soles: The iDScore_plantarLinda Tognetti, Sofia Lo Conte, Simone Leonardelli, et al.
The Journal of Dermatological Treatment|October 27, 2024
Effectiveness of tildrakizumab 200 mg: an Italian multicenter studyAnnunziata Dattola, Nicoletta Bernardini, Francesca Svara, et al.
Patient Preference and Adherence|November 26, 2021
Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in ItalyGiuseppe Argenziano, Paolo Amerio, Maria Grazia Aragone, et al.
Pageof 29

Showing results (181-190 of 284) with videos related to

Sort By:
Pageof 29
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 9, 2026
Age-specific melanoma risk associated with nevi: a pooled analysis from the M-SKIP projectGiulia Doi, Aurora Gaeta, Simone Ribero, et al.
Life (Basel, Switzerland)|January 8, 2025
Correction: Tognetti et al. Pattern Analysis of Benign and Malignant Atypical Melanocytic Skin Lesions of Palms and Soles: Variations of Dermoscopic Features According to Anatomic Site and Personal Experience. <i>Life</i> 2024, <i>14</i>, 659Linda Tognetti, Alessandra Cartocci, Elvira Moscarella, et al.
Cancers|June 13, 2025
Clinical and Histological Predictors of Advanced Basal Cell Carcinoma Recurrence After Complete Response to Hedgehog Pathway Inhibitors: A Retrospective Multicenter Observational StudyMaria Mannino, Massimiliano Scalvenzi, Alessandro Di Stefani, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 12, 2018
MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the melanostrum consortiumAlexander J Stratigos, Maria Concetta Fargnoli, Arcangela De Nicolo, et al.
The Journal of Dermatological Treatment|November 3, 2025
Baricitinib for adult atopic dermatitis: real-world effectiveness, safety, and response predictorsNiccolò Gori, Lucia Di Nardo, Elena Ippoliti, et al.
Acta Dermato-Venereologica|December 3, 2020
Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME StudyMarina Talamonti, Giovanna Malara, Ylenia Natalini, et al.
Biomedicines|October 27, 2022
Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective StudyMartina Burlando, Gabriella Fabbrocini, Claudio Marasca, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 20, 2025
A clinical-dermoscopic risk scoring model for early melanoma of the soles: The iDScore_plantarLinda Tognetti, Sofia Lo Conte, Simone Leonardelli, et al.
The Journal of Dermatological Treatment|October 27, 2024
Effectiveness of tildrakizumab 200 mg: an Italian multicenter studyAnnunziata Dattola, Nicoletta Bernardini, Francesca Svara, et al.
Patient Preference and Adherence|November 26, 2021
Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in ItalyGiuseppe Argenziano, Paolo Amerio, Maria Grazia Aragone, et al.
Pageof 29